Reata Pharmaceuticals Inc sell BiotechBee
Summary
This prediction ended on 07.02.23 with a price of €47.20. The SELL prediction by BiotechBee finished with a performance of 22.92%. BiotechBee has 70% into this predictionReata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on identifying, developing, and commercializing novel therapeutics for patients with severe and life-threatening diseases. The company's primary business areas include drug discovery and development in fields such as cardiovascular, fibrotic, mitochondrial, and neurodegenerative diseases. With a strong emphasis on research and innovation, Reata Pharmaceuticals seeks to deliver cutting-edge treatments that address unmet medical needs, improve patient outcomes, and significantly impact the lives of those suffering from rare and debilitating conditions. As a publicly traded company, Reata Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol "RETA."
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Reata Pharmaceuticals Inc | - | - | - |
iShares Core DAX® | 1.665% | 0.362% | 17.556% |
iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% |
iShares Nikkei 225® | 2.620% | 1.174% | 17.273% |
iShares S&P 500 | -0.091% | -1.597% | 24.739% |
According to BiotechBee what are the pros and cons of Reata Pharmaceuticals Inc for the foreseeable future?
Pros
Cons
Comments by BiotechBee for this prediction
In the thread Reata Pharmaceuticals Inc diskutieren
In the thread Trading Reata Pharmaceuticals Inc
Stopped prediction by BiotechBee for Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc
28.06.23
31.01.26
30.07.23
Reata Pharmaceuticals Inc
07.02.23
07.02.25
05.05.23
Reata Pharmaceuticals Inc
08.09.22
31.12.24
21.10.22